当前位置: 首页 » 论文全文
←返回首页
期刊信息:
《药学服务与研究》2018年, 第18卷, 第4期, 第282-287页
标题:
术前高剂量他汀类药物减少心血管事件有效性的荟萃分析
DOI:
10.5428/pcar20180413
作者:
1. 曹爱霖(第二军医大学长海医院药学部 上海 200433 601905411@qq.com)
2. 钱皎(第二军医大学长海医院药学部 上海 200433 )
3. 王卓(第二军医大学长海医院药学部 上海 200433 wangzhuo088@163.com)
摘要:
摘要  目的:系统评价亚洲人群在经皮冠状动脉介入(PCI)术前,负荷高剂量他汀类药物治疗急性冠脉综合征减少心血管事件的有效性。方法:应用计算机检索PubMed、EMBase、Cochrane图书馆公开发表的相关随机对照试验,对符合纳入标准的临床研究进行资料提取。使用Cochrane系统评价员手册5.1.0进行质量评价,采用Rev Man 5.3统计软件进行荟萃(meta)分析。结果:最终纳入7项随机对照试验,共1381例入院前未服用他汀类药物的患者,其中试验组(负荷他汀组)689例,对照组692例。试验组的主要心脏不良事件(MACE)发生率显著低于对照组,差异有统计学意义(P<0.001)。同时,PCI术前负荷剂量对围手术期心肌梗死(PMI)发生率有影响,试验组的PMI发生率显著低于对照组,差异有统计学意义(P<0.001)。结论:对于亚洲的急性冠脉综合征患者,PCI术前给予负荷剂量他汀类药物能有效降低患者术后30 d的心血管事件发生率。
欢迎阅读《药学服务与研究》!您是该文第 614 位读者!
若需在您的论文中引用此文,请按以下格式著录参考文献:
中文著录格式 曹爱霖,钱皎,王卓. 术前高剂量他汀类药物减少心血管事件有效性的荟萃分析[J]. 药学服务与研究. 2018; 18(4): 282-287.
英文著录格式 CAO AiLin,QIAN Jiao,WANG Zhuo. Efficacy of high-dose statins administration before surgery on the reduction of cardiovascular events: a meta analysis[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2018; 18(4): 282-287.
参考文献:
1. 中华医学会心血管病学分会介入心脏病学组,中国医师协会心血管内科医师分会血栓防治专业委员会,中华心血管病杂志编辑委员会.中国经皮冠状动脉介入治疗指南(2016)[J]. 中华心血管病杂志, 2016,44(5):382-400.
2. 中华医学会心血管病学分会,中华心血管病杂志编辑委员会.非ST段抬高型急性冠状动脉综合征诊断和治疗指南(2016)[J].中华心血管病杂志, 2017,45(5):359-376.
3. 中华医学会心血管病学分会,中华心血管病杂志编辑委员会.急性ST段抬高型心肌梗死诊断和治疗指南[J].中华心血管病杂志, 2015,43(5):380-393.
4. Nomoto K, Watanabe I, Oba T, et al. Safety and efficacy of sirolimus-eluting stent in patients with acute coronary syndrome undergoing emergency procedures[J]. Circ J,2008,72(7):1054-1058.
5. 白瑾,祖凌云,张永珍,等.择期经皮冠状动脉介入治疗术前负荷剂量他汀治疗对经皮冠状动脉介入治疗相关炎症及心肌损害的影响[J].中国医学前沿杂志(电子版), 2011,3(5):36-41.
6. Rosenson R S, Tangney C C, Casey L C.Inhibition of proinflammatory cytokine production by pravastatin[J].Lancet, 1999,353(9157):983-984.
7. Mason J C, Ahmed Z, Mankoff R, et al. Statin-induced expression of decay-accelerating factor protects vascular endothelium against complement-mediated injury[J]. Circ Res,2002,91(8):696-703.
8. Yokoyama S, Ikeda H, Haramaki N, et al. HMG-CoA reductase inhibitor protects against in vivo arterial thrombosis by augmenting platelet-derived nitric oxide release in rats[J]. J Cardiovasc Pharmacol,2005,45(4):375-381.
9. Patti G, Pasceri V, Colonna G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial[J]. J Am Coll Cardiol,2007,49(12):1272-1278.
10. ZHANG Feng,DONG LiLi, GE JunBo. Effect of statins pretreatment on periprocedural myocardial infarction in patients undergoing percutaneous coronary intervention:a meta-analysis[J]. Ann Med, 2010,42:171-177.
11. LIU YangChun, SU Qiang, LI Lang. Efficacy of short-term high-dose atorvastatin pretreatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a meta-analysis of nine randomized controlled trials[J]. Clin Cardiol, 2013, 36(12):E41-E48.
12. WANG Le, PENG PingAn, ZHAO Ou, et al. High-dose statin pretreatment decreases periprocedural myocardial infarction and cardiovascular events in patients undergoing elective percutaneous coronary intervention:a meta-analysis of twenty-four randomized controlled trials[J]. PLoS One,2014,9(12):e113352.
13. 霍勇,葛均波,韩雅玲,等. 急性冠状动脉综合征患者强化他汀治疗专家共识[J].中国介入心脏病学杂志, 2014,22(1):4-6.
14. Jang Y S, ZHU JunRen, Ge JunBo, et al. Preloading with atorvastatin before percutaneous coronary intervention in statin-nave Asian patients with non-ST elevation acute coronary syndromes:A randomized study[J]. J Cardiol,2014,63(5):335-343.
15. ZHENG Bo, JIANG Jie, LIU HuiLiang, et al. Efficacy and safety of serial atorvastatin load in Chinese patients undergoing elective percutaneous coronary intervention: results of the ISCAP (intensive statin therapy for Chinese patients with coronary artery disease undergoing percutaneous coronary intervention) randomized controlled trial[J]. Eur Heart J Suppl, 2015,17(Suppl B):B47-B56.
16. Stong N J, Robinson J G, Lichtenstein A H, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines[J].J Am Coll Cardiol,2014,63(25):2889-2934.
17. Higgins J P T, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0[EB/OL]. (2011-03)[2017-10]. http://handbook-5-1.cochrane.org/.
18. Kim J S, Kim J, Choi D, et al. Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction:the statin STEMI trial[J]. JACC Cardiovasc Interv,2010,3(3):332-339.
19. LUO Jun, LI Jiang, SHEN XiangQian,et al. The effects and mechanisms of high loading dose rosuvastatin therapy before percutaneous coronary intervention in patients with acute coronary syndrome[J]. Int J Cardiol,2013,167(5):2350-2353.
20. WANG XueZhong, WANG YueSong, WANG ShaoJun, et al. The effects of 80 mg loading dose atorvastatin pretreatment on myocardial protection during percutaneous coronary intervention in elderly patients with non-ST-segment elevation acute coronary syndrome[J]. Heart,2012,98(Suppl 2):E1-E319.
21. WANG ZhengZhang, DAI HongYan, XING MingQing, et al. Effect of a single high loading dose of rosuvastatin on percutaneous coronary intervention for acute coronary syndromes[J]. J Cardiovasc Pharmacol Ther, 2013,18(4):327-333.
22. YU XingLong, ZHANG HaiJuan, REN ShaoDa, et al. Effects of loading dose of atorvastatin before percutaneous coronary intervention on periprocedural myocardial injury[J]. Coron Artery Dis, 2011, 22(2):87-91.
23. Yun K H, Jeong M H, Oh S K,et al. The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome[J]. Int J Cardiol, 2009,137(3):246-251.
24. Sciascio D G, Patti G, Pasceri V, et al. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention:results of the ARMYDA-RECAPTURE (atorvastatin for reduction of myocardial damage during angioplasty) randomized trial[J]. J Am Coll Cardiol,2009,54(6):558-565.
25. Briguori C, Visconti G, Focaccio A,et al. Novel approaches for preventing or limiting events (Naples) Ⅱ trial:impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction[J]. J Am Coll Cardiol,2009,54(23):2157-2163.
26. Sardella G, Lucisano L, Mancone M, et al. Comparison of high reloading ROsuvastatin and atorvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of MyocArdial periprocedural necrosis. The ROMA Ⅱ trial[J].Int J Cardiol,2013,168(4):3715-3720.
27. Roffi M, Patrono C, Collet J P, et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation:task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)[J]. Eur Heart J, 2016, 37(3):267-315.
28. 张明,李轩,陈宏,等.中国患者应用大剂量阿托伐他汀安全性的Meta分析[J].中国介入心脏病学杂志, 2016,24(2):88-95.